Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.

Détails

ID Serval
serval:BIB_F9E1DF7E3203
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.
Périodique
Journal of Neurology
Auteur(s)
Vulliemoz S., Lurati-Ruiz F., Borruat F.X., Delavelle J., Koralnik I.J., Kuntzer T., Bogousslavsky J., Picard F., Landis T., Du Pasquier R.A.
ISSN
1468-330X (Electronic)
ISSN-L
0022-3050
Statut éditorial
Publié
Date de publication
09/2006
Peer-reviewed
Oui
Volume
77
Numéro
9
Pages
1079-1082
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
Progressive multifocal leucoencephalopathy (PML), a demyelinating disease caused by the JC virus (JCV), occurs in immunosuppressed patients and carries a poor prognosis. A favourable outcome is reported in two patients with PML and dermatomyositis. Immunosuppressive drugs were stopped in patient 1 but could only be partially tapered in patient 2. The JCV-specific CD8+ T cell response was strong in patient 1 and weak in patient 2. Both were treated with cytosine-arabinoside, and patient 2 was also treated with mirtazapine, a 5HT2A receptor antagonist. Combination of these drugs might be helpful to treat HIV-negative patients with PML.
Mots-clé
Adrenergic alpha-Antagonists/therapeutic use, Cytarabine/therapeutic use, Dermatomyositis/complications, Female, Humans, Immunosuppressive Agents/therapeutic use, Leukoencephalopathy, Progressive Multifocal/drug therapy, Leukoencephalopathy, Progressive Multifocal/etiology, Male, Mianserin/analogs & derivatives, Mianserin/therapeutic use, Middle Aged, Treatment Outcome
Pubmed
Web of science
Création de la notice
28/01/2008 12:37
Dernière modification de la notice
20/08/2019 16:25
Données d'usage